ImmunoPrecise Antibodies Soars 7.71% on LENSai Breakthrough

On July 7, 2025, Immunoprecise's stock surged by 7.71% in pre-market trading, reflecting significant investor optimism and market confidence in the company's recent advancements.

ImmunoPrecise Antibodies' LENSai platform has made a significant breakthrough in epitope mapping accuracy. This platform, powered by IPA's patented HYFT technology, has demonstrated the ability to accurately predict binding on 17 different epitopes, showcasing its potential to revolutionize the field of antibody development.

ImmunoPrecise is actively integrating the LENSai platform into collaborations with major pharmaceutical and biotech companies. This strategic move not only validates the platform's capabilities but also positions ImmunoPrecise as a key player in the biotech industry, driving further growth and innovation.